147 related articles for article (PubMed ID: 36738305)
21. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
Kim SY; Lee JS; Kang J; Morita S; Park YS; Sakamoto J; Muro K; Xu RH; Kim TW
Oncologist; 2021 Jun; 26(6):e954-e962. PubMed ID: 33644953
[TBL] [Abstract][Full Text] [Related]
22. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.
Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H
Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571
[TBL] [Abstract][Full Text] [Related]
23. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
[TBL] [Abstract][Full Text] [Related]
24. Effects of vonoprazan on gastric PH and clinical course after gastric ESD: A retrospective and prospective study.
Suto D; Yoshida M; Otake T; Ichiishi E; Sato K; Murata K; Ebinuma H; Odaira H; Suzuki Y; Kohgo Y
Ann Med Surg (Lond); 2020 Dec; 60():27-30. PubMed ID: 33101669
[TBL] [Abstract][Full Text] [Related]
25. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
Kaohsiung J Med Sci; 2018 Aug; 34(8):456-460. PubMed ID: 30041763
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Yang S; Deng W; Xie Z; Chen J
Medicine (Baltimore); 2022 Nov; 101(47):e31807. PubMed ID: 36451489
[TBL] [Abstract][Full Text] [Related]
27. Real-world outcomes associated with vonoprazan-based
Howden CW; Cook EE; Swallow E; Yang K; Guo H; Pelletier C; Jacob R; Sugano K
Therap Adv Gastroenterol; 2023; 16():17562848231168714. PubMed ID: 37153499
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Kiyotoki S; Nishikawa J; Sakaida I
Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
[TBL] [Abstract][Full Text] [Related]
29. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
[TBL] [Abstract][Full Text] [Related]
30. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Kagawa T; Iwamuro M; Ishikawa S; Ishida M; Kuraoka S; Sasaki K; Sakakihara I; Izumikawa K; Yamamoto K; Takahashi S; Tanaka S; Matsuura M; Hasui T; Wato M; Inaba T
Aliment Pharmacol Ther; 2016 Sep; 44(6):583-91. PubMed ID: 27464849
[TBL] [Abstract][Full Text] [Related]
31. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
32. Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis.
Jaruvongvanich V; Poonsombudlert K; Ungprasert P
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1416-1421. PubMed ID: 29985791
[TBL] [Abstract][Full Text] [Related]
33. Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study.
Kambara H; Hosohata K; Nakatsuji T; Ueno S; Oyama S; Inada A; Niinomi I; Wakabayashi T; Iwanaga K
Pharmazie; 2020 Oct; 75(10):527-530. PubMed ID: 33305731
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
35. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis.
Maruoka D; Arai M; Kasamatsu S; Ishigami H; Taida T; Okimoto K; Saito K; Matsumura T; Nakagawa T; Katsuno T; Yokosuka O
Dig Endosc; 2017 Jan; 29(1):57-64. PubMed ID: 27492962
[TBL] [Abstract][Full Text] [Related]
36. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Oshima T; Igarashi A; Nakano H; Deguchi H; Fujimori I; Fernandez J
J Clin Gastroenterol; 2022 Jul; 56(6):493-504. PubMed ID: 35470298
[TBL] [Abstract][Full Text] [Related]
37. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
38. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
39. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
